BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Raziel Therapeutics Launches Phase 3 Study in China for RZL-012, an Injectable Fat Reduction Treatment

Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phas...

March 05, 2025 | News

Elsevier Expands ClinicalKey AI with EHR and HIT Integrations to Enhance Clinician Workflows

Elsevier, a global leader in health information and data analytics, has announced further enhancements to ClinicalKey AI, the company's leading generative ...

March 04, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...

March 03, 2025 | News

MojiaBio and A*STAR Partner to Develop SGD 44.8 Million Sustainable Biomanufacturing Technology Platform in Singapore

MojiaBio, a global leader in green chemistry and sustainable biomanufacturing, has announced a strategic partnership with the Agency for Science, Technolog...

March 03, 2025 | News

China Fapon Biopharma secures US FDA IND approval for FP008 a first-in-class immunocytokine for resistant solid tumors

Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...

March 03, 2025 | News

Neopharma Partners with AusChain to Enable Blockchain-Powered Drug Test Kit Traceability

Neopharma Technologies Ltd (Neopharma) is pleased to announce a strategic partnership with AusChain Pty Ltd, a global leader in scalable blockchain so...

February 28, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

WuXi XDC Expands Partnership with LigaChem to Accelerate Next-Gen ADC Development

WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiz...

February 26, 2025 | News

HBM Alpha Therapeutics Secures $395M Licensing Deal to Advance CRH-Targeting Therapy

HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaborati...

February 26, 2025 | News

Telix’s Kidney Cancer Imaging Agent Gains FDA Priority Review, Eyes 2025 Launch

Telix Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for TLX25...

February 26, 2025 | News

Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

February 25, 2025 | News

LabConnect and ACL Specialised Trials Partner to Strengthen Clinical Trial Support in Australia and APAC

LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic partnership to expand support of clinical trials in Aus...

February 25, 2025 | News

Akeso Begins Phase III Trial of Ivonescimab for First-Line Treatment of Advanced Triple-Negative Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, ran...

February 24, 2025 | News

Chime Biologics and Mabgeek Advance MG-K10 to U.S. Phase III Trials for Atopic Dermatitis and Asthma

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, announced its continued collaboration with Mabgeek ...

February 24, 2025 | News

Stay Connected